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We summarized the most recent findings on the role of autophagy in antiviral immune response. We described how viruses have
developed strategies to subvert the autophagic process. A particular attention has been given to Epstein-Barr and Kaposi’s sarcoma
associated Herpesvirus, viruses studied for many years in our laboratory. These two viruses belong to 𝛾-Herpesvirus subfamily
and are associated with several human cancers. Besides the effects on the immune response, we have described how autophagy
subversion by viruses may also concur to the enhancement of their replication and to viral tumorigenesis.
1. Autophagy and the Immune Response
According to the paradigm of antigen processing by the
antigen presenting cells (APC), peptides arising from intra-
cellular proteins are presented via class I MHC molecule.
This occurs after they are degraded via proteasome and trans-
ported by transporters associated with antigen processing
(TAPs). Differently, peptides that originate from extracellu-
lar antigens are delivered to the late endosomal/lysosomal
compartment, where they are degraded by the lysosomal
proteases and then presented in association with class II
MHC. In the lysosomes, the invariant chain, which blocks
class IIMHC, is also degraded, rendering theMHCmolecules
available for peptide loading. Besides the differences in the
sites of origin and processing, peptides presented via class I
or II MHC activate different populations of T lymphocytes,
which are CD8+ or CD4+, respectively [1]. However, excep-
tions to this model have been described and, for example,
dendritic cells (DCs), the most powerful APC [2], are able
to present extracellular antigens also via class I MHC. This
event, known as cross-presentation, allows DCs to activate
both CD4+ and CD8+ T cells, in response to an extracellular
antigen [3]. On the other hand, antigens of intracellular
origin can be presented also in class II MHC, after being
delivered to the lysosomes, through double membrane vesi-
cles, called autophagosomes [4]. Autophagosomes are formed
during the induction of autophagy, a self-eating mechanism
through which cells recycle their own constituents and
survive in stressful conditions. This represents one of the
mechanisms through which autophagy may promote the
immune response. The autophagic process is regulated by
AuTophaGy-related (ATG) genes [5]. Some of them, such as
Atg1, Atg11, and Atg13, regulate autophagosome formation;
others (e.g., Atg2, Atg9, and Atg18) are required for mem-
brane flow to the expanding phagophore. The vesicle nucle-
ation is instead dependent on the class-III phosphatidylinos-
itol 3 kinase (PtdIns3K) complex formed by Vps34, Vps15,
Vps30/Atg6, and Atg14. Atg6, also named Beclin 1, represents
a protein with a pivotal role in the autophagy induction
[6] and the microtubule-associated protein light chain 3
(LC3), or Atg8, is a marker of the autophagic vacuoles
[7]. LC3 is expressed as full-length cytosolic protein and
upon autophagy induction is cleaved by Atg4 to form LC3I,
which is then conjugated to phosphatidylethanolamine (PE),
generating LC3II. This molecule, whose formation indicates
autophagy induction, is associated with the internal and
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external membrane of autophagosome and, by interacting
with adaptor molecules, such as p62/SQSTM1, promotes
uptake and degradation of both cargo and adaptors into the
lysosomes [8]. Indeed, autophagosomes fuse with lysosomes
transporting intracellular proteins in the last autophagic
steps. Among them, also viral antigens can end up in the
lysosomes, in virally infected cells. Here peptides derived
from their degradation may be complexed and presented in
association with class II MHCmolecules. Another important
role of autophagosomes is to transport entire viral particles
to the endosomal/lysosomal compartment, to be degraded
and eventually eliminated, a process known as xenophagy
[9]. After entering the cells, pathogens can be directly deliv-
ered to the lysosomes through phagosomes. Alternatively,
phagosomes as well as free viral particles can be engulfed
by the double membrane vesicles of autophagosomes, before
reaching the lysosomes.The latter process is under the control
of the ATG genes, even if it represents a particular form
of autophagy aimed at the antimicrobial defense [10]. In
addition, autophagy facilitates the pathogen engagement of
intracellular TLRs and the consequent release of cytokines,
such as type I IFN [11]. The binding of TLRs as well as other
molecules involved in the immune response, for example,
CD46, by ligands or pathogens that use them as receptors,
also triggers autophagy. This has been reported for Epstein-
Barr virus (EBV) that binds TLRs [12] and for measles virus
that uses CD46 as receptor [13]. Autophagy has been also
shown to contribute to measles virus infectivity [14]. Intrigu-
ingly, since CD46 represents the cellular receptor also for
human Herpes-virus 6 (HHV6) [15], it would be interesting
to investigate the impact on autophagy of CD46 engagement
byHHV6. As if the role of autophagy in the immune response
was not enough important, it has been recently reported
that autophagy is induced by GM-CSF in monocytes and
that it stimulates monocyte differentiation into functional
macrophages and DCs. Besides that, autophagy also plays an
essential role in preventing apoptosis of these cells [16].
2. Autophagy Manipulation by Viruses
Among the strategies that allow viruses to escape from the
immune control, the impairment of monocyte differentiation
into functional DCs represents a common one [17–19]. Based
on the recent finding, suggesting that autophagy is involved in
monocyte differentiation inmacrophages and DCs, the inter-
ference with the autophagic process could represent one of
the underlyingmechanisms responsible for such impairment.
This strategy has been recently reported to be exploited by
Human Hepatitis C virus (HCV), whose infection of human
monocytes results in a reduction of lysosomal cathepsins, in
an autophagic block at the late steps, and, as a consequence,
in an impairment of DC differentiation [20]. HCV-mediated
reduction of lysosomal acidification, as result of cathepsin
release, has been reported also in other cell types [21]. How-
ever, autophagy can contribute to HCV replication since the
autophagosomalmembranes can be used for viral production
[22]. Given the importance of autophagy in the immune
response, it is not surprising that viruses have evolved strate-
gies to interferewith it, in order to avoid their elimination into
the lysosomes, impair the production of antiviral cytokines,
reduce the presentation of their antigens, and, as described
for HCV, alter DC differentiation. This is a must for viruses
to persist in the infected host, sometimes with pathological
consequences. All the steps of the autophagic process, from
the autophagosome formation to the lysosomal degradation
of their content [23], can be manipulated by viruses [24, 25]
(Figure 1). It has been described that it depends on the virus
types, on the phase of their life cycle, and on the host cell
that they infect. For example, Human Immunodeficiency
Virus [23], a single-stranded RNA lentivirus belonging to
the Retroviridae family, is able to induce the initial phases
of autophagy by Env, an envelope fusogenic protein. On the
other hand, it blocks the late autophagic phases to enhance
viral production by expressing Nef, an accessory protein that
interferes with the autophagosomalmaturation [24, 25]. Dur-
ing the replicative phase of their life cycle, also herpesviruses
such as EBV and Kaposi’s Sarcoma Human Herpesvirus
(KSHV) can promote autophagy and exploit the autophagic
machinery to enhance their replication [26–28]. To do so,
they promote the first autophagic steps and block the last
ones. This strategy allows them to avoid being delivered into
the destructive environment of the lysosomes and to usurp
the autophagic machinery for viral transportation through
the cell cytoplasm [22, 26, 29]. Pathways involved in the
autophagy induction, such as PKR/EIF2 alpha and m-Tor,
can be also targeted by viruses belonging to the Herpesvirus
family, for example, Herpes Simplex virus-1 (HSV-1) [30–
32] and cytomegalovirus (HCMV) [33]. Also Beclin 1, a
key molecule involved in several steps of the autophagic
process [6], can be bound and altered in its function by viral
proteins such as vBcl2 of KSHV or ICP 34.5 of HSV-1 [34–
36]. All these strategies allow viruses to block autophagy
induction during infection of the host cells. Differently,
another Herpesvirus, Varicella-Zoster virus (VZV), has been
recently reported to successfully infect target cells without
blocking the autophagic process. Indeed ICP 34.5 or US11, the
two proteins responsible for the block of autophagy by HSV1,
are not present in VZV although both viruses belong to the
same subfamily [37].
3. Herpesviruses
Herpesviruses are large, double strand DNA viruses having
a common particle structure [38]. To date eight human
Herpesviruses have been identified and classified into three
subfamilies (alpha, beta, and gamma) based on their growth
characteristics and tissue tropism [39]. The 𝛼-subfamily
includes the neurotropic viruses Herpes Simplex viruses
(HSV) 1 and 2 and Varicella-Zoster virus (VZV). Human
cytomegalovirus (HCMV) and the human Herpesviruses 6
and 7 are members of the 𝛽-subfamily, while EBV and KSHV
are members of the 𝛾-subfamily [40]. A common feature
shared by all human Herpesviruses is the viral persistence
into host and the possibility to undergo two alternative life
cycle programs, namely, latency and lytic replication. During
latency the viral genome is retained as a circular episome in
the nucleus and no viral progeny is produced. Furthermore,
in the course of latent infection a limited set of genes is
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Figure 1: Examples of autophagy manipulation by human viruses.
expressed in order to reduce immune recognition. In contrast
to latency, the Herpesvirus lytic program is characterized by
a regulated cascade of viral gene expression accompanied by
viral production and killing of infected cells [23]. Although
most Herpesviruses have been reported to interfere with the
autophagic process, the next part of this review will focus on
the interplay between autophagy and 𝛾-Herpesviruses, given
that our laboratory has for long timeworked on the virus-host
interaction of these viruses associated with several human
cancers.
4. Epstein-Barr Virus (EBV)
As for other Herpesviruses, EBV infection can be latent or
lytic [41, 42]. During latency the EBV genome is retained as
a circular episome in the cell nuclei and upon appropriate
stimuli the virus switches into the lytic replication program.
It is known that EBV infects primarily human B lymphocytes
and epithelial cells; however, its infection can also occur in
other cells with a central role in the immune response [43],
such as monocytes and DCs [44, 45]. The in vitro infection
of monocytes induces apoptosis and results in an impairment
of DC development [45, 46], although the underlyingmecha-
nisms have not been investigated in these studies. Therefore,
the autophagic pathway could be investigated in these cells
since, as previously described, a block of autophagy can
switch cell differentiation into cell death in monocytes DCs
[16]. These are the most powerful cells in the priming of the
CD8+ T cell response, playing a pivotal role in control of
the EBV infection [47]. Besides cytotoxic T cells, DCs are
able to activate a CD4+ T cell-mediated immune response
against the EBV antigens, such as EBNA1, through the
mechanism of cross-presentation [48]. Autophagy has been
shown to be essential for class IIMHCpresentation of EBNA1
protein. The block of autophagy resulted in an accumulation
of this protein in the intracellular autophagosomes and,
more importantly, in a reduction of EBNA1 recognition by
EBNA1 specific CD4+ T cells [49]. The involvement of
autophagy in EBNA 1 presentation was later confirmed by
a more recent study [50]. Regarding the EBV interaction
with plasmacytoid subpopulation of DCs (pDCs), the main
type I IFN producing cells [51], it has been reported that
autophagy is essential for IFN release in response to the EBV
infection. Autophagy is stimulated by the virus and facilitates
its interaction with TLR7 and TLR9 PPRs, both located
in the endosomal/lysosomal compartment and essential for
EBV recognition by these cells. However, although EBV
stimulates autophagy and IFN release, its infection results in
an impairment of pDC maturation [12]. Since it has been
reported that EBV downregulates TLR 9 in B cells [52] and
that this effect is mediated by two EBV proteins, namely,
latent membrane protein 1 (LMP1) [53] and BGLF5 [54], it
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would be interesting to investigate TLR9 expression levels in
the pDCs EBV-infected versus uninfected control cells.
EBV is associated with several different human cancers of
B and epithelial cell origin, such as posttransplant lympho-
proliferative disorder (PTLD), Hodgkin and non-Hodgkin
lymphomas, nasopharyngeal carcinoma (NPC), and some
forms of gastric carcinoma [55]. Besides its strong association
with some human cancers, EBV infects and establishes a
life-long asymptomatic infection in 95% of adult healthy
population [56], reducing to the minimum or not expressing
any protein, in order to escape from the immune recognition.
Among the viral antigens, only the EBV latent nuclear antigen
1 (EBNA1) expression is required for the maintenance of the
viral episome in the EBV infected human B cells [57] and
this is the only protein always expressed in EBV-associated
malignancies.This protein has been demonstrated to activate
both CD4+ T cells [44], being presented via class II MHC
[49] and CD8+ T cells [58], although for long time it
has been considered invisible to the immune system [48].
As previously described, autophagy is essential for EBNA1
antigen presentation via class II MHC while, interestingly, it
does not seem to play a role in the class II MHC presentation
of two other EBV latent nuclear proteins, EBNA2 and EBNA
3C, both expressed only in pathological conditions [59].
The most oncogenic EBV latent protein, LMP1, has been
reported to regulate its own expression by inducing or
inhibiting autophagy. When LMP1 is highly expressed in B
cells, autophagy is stimulated and promotes degradation [60].
Given that LMP1 plays an important role in EBV-induced
oncogenesis, the stimulation of autophagy could be used
as a strategy to reduce the expression of this protein and
consequently to affect the EBV-driven tumorigenesis.
5. Kaposi’s Sarcoma-Associated
Herpesvirus (KSHV)
KSHV or Human Herpesvirus-8 (HHV-8) is the last human
𝛾-Herpesvirus identified to date [61]. It shows two alternative
life cycle programs, latent and lytic [62–64]. Generally,
latency is the KSHV default program within 48–72 h postin-
fection depending on target cells. In vivo, KSHV mainly
infects endothelial and B cells and establishes a lifelong
latency in B lymphocytes of infected individuals, escaping
from the host immune response [65, 66]. Several KSHV
latent and lytic proteins are involved in immune evasion, in
preventing apoptosis and blocking autophagy as well as in
transformation [67]. KSHV is the etiologic agent of Kaposi’s
sarcoma (KS) [61], a multifocal angioproliferative disorder
arising from KSHV-infected endothelial cell [68], and of
lymphoproliferative disorders, such as primary effusion lym-
phomas (PELs), a non-Hodgkin B cell lymphoma localized in
body cavities [66], and the plasma cell variant of multicentric
Castleman disease (MCD) [69]. It is important to underline
that, although KSHV is detectable in all KS lesions, regardless
of disease stage or clinical variant, the virus is necessary
but not sufficient for the development of this tumor [67,
68]. Typical of KS are the spindle cells, derived from the
endothelial cells. The majority of spindle cells are latently
infected by KSHV and only a small percentage of these cells
express viral lytic antigens [68, 70]. However, it is currently
believed that lytic replication is necessary to support KS
lesion formation and maintenance [68, 71–74]. In addition,
viral replication allows the secretion of proinflammatory
and/or proangiogenic factors that create the inflammatory
microenvironment essential in KS pathogenesis [68, 75].
Monocytes are among the inflammatory cells found in KS
lesions and a study, based on immunohistochemical staining
and in situ hybridization, reported that these cells are KSHV
infected [76]. The virus has also been detected in peripheral
T-cells and macrophages [77, 78].
As other Herpesviruses, KSHV has to cope with innate
and adaptive immunity in order to establish a persistent
infection in immunocompetent host. Latency is one of the
strategies used by KSHV since viral gene expression is
reduced. Conversely, during its lytic cycle, a high number of
immunogenic proteins are produced [71, 79]. The relevance
of the equilibrium between KSHV lytic cycle and host
immunity is indicated by the increased viral replication and
the development of KSHV-related malignancies in immuno-
suppressed patients [80–82]. About 25% of KSHV proteins
are involved in KSHV immune evasion mechanisms [79]
and, although most of these belong to lytic cycle, both latent
and lytic proteins are able to hijack innate and adaptive
immune response [67].They can indeed inhibit complement-
mediated lysis of infected cells and the IFN I signaling,
deregulate the inflammatory cytokine/chemokine networks,
and interferewith antigen presentation [67, 79, 83–85]. pDCs,
monocyte-derived dendritic cells, and monocytes are among
the cell types infected by KSHV [19, 86, 87]. As consequence
of the infection, a reduction of costimulatory molecules
as well as a deregulation of the cytokine release and an
impairment of allostimulatory capacity can occur [19, 76, 87–
90]. In vivo, DC functional impairment has been reported
in patients with classical KS [91] and a reduction of pDCs
was observed in AIDS-KS in comparison to KS negative
HIV-1 infected individuals [92]. Moreover, the number of
Langerhans cells is also decreased in KS lesions compared
to normal skin [93]. Furthermore, it has been reported
that the signal transducer and activator of transcription 3
(STAT3) activation in noninfected monocytes/macrophages
leads to a block of autophagy and consequent dysfunction,
due to the cytokines released during HIV infection [94].
Interestingly, STAT3 inhibitors are potent autophagy inducers
[95]. In this context we showed that KHSV is able to activate
STAT3 pathway in DCs by binding to its receptor on these
cells, namely, the type II C-type lectin, dendritic cell-specific
ICAM-3 grabbing nonintegrin (DC-SIGN; CD209) [87, 96].
Besides, we showed that STAT3 activation led to a block of the
autophagic flux, as demonstrated by the reduced expression
of LC3II and the increased level of p62 [96]. In addition,
looking for a possible mechanism responsible for the block
of autophagy mediated by STAT3 activation in DCs exposed
to KSHV, we found an upregulation of Mcl-1 [96, 97]. This
is one of the proteins able to bind and sequester Beclin 1,
hampering its essential role in autophagosome formation.
Remarkably, STAT3 inhibition by AG490 was able to prevent
the effects on p62, LC3II, and Mcl-1 [96]. In agreement, a
previous paper has shown that the inhibition of STAT3 by
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Sorafenib resulted in a downregulation of Mcl-1, disruption
of Beclin 1-Mcl-1 complex, and reversion of the autophagic
block in hepatocarcinoma cells [98]. Of note, the autophagic
block occurred also in the presence of UV-inactivated KSHV
[96], indicating that neither vBCL2 nor vFLIP expression was
required [34, 96, 99, 100]. Concomitantly to the autophagic
block induced by KSHV-mediated STAT3 activation, we
also observed a reduction of IL12p70 release in response
to LPS stimulation and a higher production of IL-10, IL-
6, and IL-23 [96]. This cytokine pattern skews the Th1/Th2
profile towards Th2 [88] and/or Th17 [101], promoting
immunosuppression and inflammation. Therefore, STAT3
activation could be one of the molecular mechanisms under-
lying KSHV-mediated immunosuppression in DCs. Indeed,
STAT3 activation correlates with an immunosuppressive
phenotype and DC dysfunction in the KSmicroenvironment
[102] and in the peripheral blood of tumor bearing patients
[103, 104]. Several papers have investigated the interplay
between KSHV and the autophagic pathway [79]. During
the latent phase of its life-cycle, KSHV expresses the FADD-
like interleukin-1 beta-converting enzyme inhibitory protein
(v-FLIP), a truncated homolog of the cellular FLIP, which
besides having an antiapoptotic activity [105, 106] has been
recently shown to block the autophagic flux. It competes
with LC3 for binding to ATG3, thereby preventing LC3
binding and processing during autophagosome biogenesis
[100]. Furthermore, the inhibition of vFLIP binding to ATG3
reduced the size of KSHV positive tumor in mice [100].
It has also been demonstrated that v-FLIP suppression of
autophagy counteracts v-cyclin-induced cellular senescence
[107, 108]. v-cyclin is a KSHV latent protein that deregulates
cell cycle, causes aberrant host DNA replication, and triggers
theDNAdamage responses (DDRs) [109]. Besides vFLIP, two
KSHVproteins expressed during the lytic cycle, vBcl2 andK7,
can interfere with autophagy. vBcl2 is a homolog of cellular
Bcl-2 that inhibits both apoptosis [99, 110] and autophagy
[34, 35]. As its cellular counterpart, vBcl2 negatively regulates
autophagy by binding Beclin 1 [34]. Alwayswithin the context
of the lytic cycle, recent evidence suggests that KSHV K7
protein prevents autophagosome maturation, by interacting
with Rubicon autophagic protein [111]. K7 is involved in
apoptosis suppression [112, 113] while Rubicon is a subunit
of the Beclin 1/UVRAG/Vps34 autophagy complex, which
regulates the autophagosome maturation and the endocytic
trafficking [114–116]. As shown by authors, K7 transfection in
epithelial cell lines promoted a greater interaction between
Rubicon and Beclin 1/UVRAG/Vps34 complex resulting in
a block of Vps34 enzymatic activity and, consequently,
of autophagosome maturation [111]. Interestingly, during
the lytic cycle KSHV exploits autophagy to enhance its
reactivation mediated by Rta immediate lytic protein [28].
Altogether, the data here reviewed suggest that KSHV has
evolved several strategies to circumvent autophagy-mediated
immune responses, to persist in infected hosts. Moreover, the
autophagic block during latency and the autophagy induction
during the lytic cycle may contribute to the pathogenesis of
KSHV associated malignancies.
6. Concluding Remarks
A better understanding of how autophagy manipulation
could influence antiviral immune response and control virus-
induced tumorigenesis might help to discover strategies
improving the outcome of the treatments of virus-associated
malignancies. Moreover, since autophagy is activated and
is involved in EBV and KSHV replication [20, 27], its
manipulation could also affect the viral particle release that
plays a role in 𝛾-Herpesvirus-associated cancers.
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